News & Updates

Show Multimedia Only

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026 by

In patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy, neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab elicits improvements in event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rate relative to neoadjuvant gemcitabine plus cisplatin, according to the phase III KEYNOTE-B15 study.

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026

Unorthodox-dosed tofacitinib, baricitinib both efficacious in paediatric alopecia

17 Mar 2026

The efficacy of unorthodox dosing regimens of tofacitinib and baricitinib is comparable among paediatric patients with moderate-to-severe alopecia areata over 24 weeks and has a manageable safety profile, reports a recent study.

Unorthodox-dosed tofacitinib, baricitinib both efficacious in paediatric alopecia

17 Mar 2026

SG study underpins benefits of hospital-at-home care model

17 Mar 2026 by

A study conducted by researchers in Singapore shows that a hospital-at-home (HaH) care model is on par with ward-based acute care in clinical outcomes but outperforms it in cost.

SG study underpins benefits of hospital-at-home care model

17 Mar 2026

Gout not a risk factor for dementia

17 Mar 2026

Gout does not contribute to an increased risk of overall dementia and may even be protective against Alzheimer's disease (AD) and cognitive impairment, according to the results of a systematic review and meta-analysis.

Gout not a risk factor for dementia

17 Mar 2026

HK study: START-FIT strategy using STRIDE regimen promising in HCC

17 Mar 2026 by

Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (START-FIT) using the STRIDE regimen of single-dose tremelimumab plus regular-interval durvalumab offers promising efficacy and is well tolerated in patients with locally advanced, unresectable hepatocellular carcinoma (HCC), a single-arm, multicentre, phase II study in Hong Kong has shown.

HK study: START-FIT strategy using STRIDE regimen promising in HCC

17 Mar 2026

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026 by

Switching to dolutegravir/lamivudine (DTG/3TC) was associated with a significantly lower rate of steatotic liver disease (SLD) compared with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people living with HIV (PLWH), according to a subgroup analysis of the PASO DOBLE trial presented at CROI 2026.

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026

Gut Health Summit: A holistic approach to gut health guarantees best outcomes

17 Mar 2026

At the recent Gut Health Summit 2026 in Kuala Lumpur, a panel of six key opinion leaders explored diverse aspects pediatric gut health, ranging from management of functional gastrointestinal disorders (FGIDs) to communication-based interventions and hypnotherapy. This feature brings together insights from Dr Arine Vlieger and Dr Ong Sik-Yong, whose sessions offered complementary perspectives on clinical practice.

Gut Health Summit: A holistic approach to gut health guarantees best outcomes

17 Mar 2026

Niacinamide lowers CVD risk in dermatology patients

16 Mar 2026

Supplementation with niacinamide appears protective against some cardiovascular events, such as myocardial infarction and cardiac arrest, suggests a study.